CLINICAL TRIAL

A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2026-05-11
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

COMPASS Pathways

Watch author

Topics and keywords

psilocybin PTSD Clinical Trial Safety Clinical Trial PTSD - Post Traumatic Stress Disorder PTSD PTSD Symptoms Post Traumatic Stress Disorder COMP360 psilocybin NOT_YET_RECRUITING

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions.International Journal of Eating Disorders · 2026-07-01 Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-06-03 Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosaJournal of Eating Disorders · 2025-05-25 The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography StudyClinicalTrials.gov · 2024-04-18 “But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin-assisted psychotherapyInternational Journal of Eating Disorders · 2023-08-07 Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a WorkshopNational Academies Press (US), Washington (DC) · 2022-08-31 CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical TrialClinicalTrials.gov · 2026-04-12 Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysisJournal of Affective Disorders · 2026-03-21